Transplant vs bortezomib and LEN/DEX in multiple myeloma
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Issues in patient-physician communication in CLL patients
Importance of prognostic factors in the treatment of CLL and how to assess them
The use of venetoclax (ABT-199) in the treatment of CLL